{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:47:26Z","timestamp":1773150446332,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) negatively affect quality of life. The \u03b11-blockers are effective for LUTS suggestive of benign prostatic hypertrophy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To analyze the effect of a uroselective \u03b11-blocker on both voiding and sexual dysfunction in Thai men with LUTS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Of 488 men with LUTS who received 10\u2003mg alfuzosin monotherapy once daily (OD) at a men's health clinic, 313 men (64%) completed 8 months of alfuzosin treatment and filled the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF)-5 questionnaires.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>The relationships among the IPSS, IIEF-5 score, and select clinical characteristics were analyzed using multiple regression analysis. To identify changes from the baseline, the chi-square or Fisher's exact test was used for categorical or dichotomous variables and a paired Student's t-test was used for continuous variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 313 men were followed up for a mean (standard deviation [SD]) of 35.6 (2.2) weeks. LUTS were categorized by IPSS as moderate in 100 patients (31.9%) and severe in 213 patients (68.1%). ED was graded according to the IIEF-5 as normal in 46 patients (14.7%), mild in 29 patients (9.3%), mild to moderate in 81 patients (25.9%), moderate in 47 patients (15.0%), and severe in 110 patients (35.1%). ED is associated with LUTS (P\u2003=\u20030.008). After 8 months of alfuzosin treatment, the mean (SD) IPSS and IIEF-5 score significantly improved from 19.95 (6.4) to 11.13 (4.6) (P\u2003&amp;lt;\u20030.001) and from 11.5 (6.9) to 14.9 (5.7) (P\u2003&amp;lt;\u20030.001), respectively. However, the IIEF-5 score did not improve significantly in patients with severe LUTS as determined using the IPSS. The most common adverse event with alfuzosin treatment was mild (dizziness, 2.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with 10\u2003mg alfuzosin OD is safe and effective in improving voiding and sexual function in Thai men with LUTS and ED.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2011.02359.x","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T21:01:18Z","timestamp":1308949278000},"page":"2582-2589","source":"Crossref","is-referenced-by-count":7,"title":["Treatment with a Uroselective \u03b11-Blocker Improves Voiding and Sexual Function: A Study in Thai Men with Lower Urinary Tract Symptoms"],"prefix":"10.1093","volume":"8","author":[{"given":"Sompol","family":"Permpongkosol","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santichai","family":"Krilad-O-Larn","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisada","family":"Ratana-O-Larn","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"key":"2024032522003553300_bb0010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1742-1241.2008.01699.x","article-title":"Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: Practice patterns according to physician specialty","volume":"62","author":"Seftel","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2024032522003553300_bb0015","first-page":"431","article-title":"Definition and diagnostic criteria of psychogenic erectile dysfunction","volume":"60","author":"Ishizu","year":"2002","journal-title":"Nippon Rinsho"},{"key":"2024032522003553300_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.ijir.3900396","article-title":"Definition and classification of erectile dysfunction: Report of the Nomenclature Committee of the International Society of Impotence Research","volume":"11","author":"Lizza","year":"1999","journal-title":"Int J Impot Res"},{"key":"2024032522003553300_bb0025","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.2174\/138161209789207051","article-title":"PDE5 inhibitors in the treatment of LUTS","volume":"15","author":"Speakman","year":"2009","journal-title":"Curr Pharm Des"},{"key":"2024032522003553300_bb0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"2024032522003553300_bb0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1046\/j.1464-410x.2000.00525.x","article-title":"The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement","volume":"85","author":"Sells","year":"2000","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0040","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Kaplan","year":"2007","journal-title":"Eur Urol"},{"key":"2024032522003553300_bb0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13685530802278128","article-title":"Increased prevalence of erectile dysfunction (ED): Results of the second epidemiological study on sexual activity and prevalence of ED in Thai males","volume":"11","author":"Permpongkosol","year":"2008","journal-title":"Aging Male"},{"key":"2024032522003553300_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinthera.2006.01.004","article-title":"Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function","volume":"28","author":"Miner","year":"2006","journal-title":"Clin Ther"},{"key":"2024032522003553300_bb0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","journal-title":"J Urol"},{"key":"2024032522003553300_bb0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1368-5031.2005.00830.x","article-title":"Efficacy and safety of alfuzosin 10\u2003mg once daily in the treatment of symptomatic benign prostatic hyperplasia","volume":"60","author":"Kuritzky","year":"2006","journal-title":"Int J Clin Pract"},{"key":"2024032522003553300_bb0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1464-410X.2008.07914.x","article-title":"Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction","volume":"102","author":"Gur","year":"2008","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0070","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1111\/j.1743-6109.2010.01743.x","article-title":"Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand","volume":"7","author":"Leungwattanakij","year":"2010","journal-title":"J Sex Med"},{"key":"2024032522003553300_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.ijir.3900859","article-title":"The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction","volume":"14","author":"Rhoden","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032522003553300_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archsurg.138.4.357","article-title":"Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity","volume":"138","author":"MacDonald","year":"2003","journal-title":"Arch Surg"},{"key":"2024032522003553300_bb0085","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(04)15856-X","article-title":"Appropriate BMI for Asian populations","volume":"363","author":"Shiwaku","year":"2004","journal-title":"Lancet"},{"key":"2024032522003553300_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.amjhyper.2004.10.003","article-title":"Erectile dysfunction and its influence on quality of life in patients with essential hypertension","volume":"18","author":"Kushiro","year":"2005","journal-title":"Am J Hypertens"},{"key":"2024032522003553300_bb0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1464-410X.2005.05347.x","article-title":"Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction","volume":"95","author":"Van Moorselaar","year":"2005","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1743-6109.2005.00132.x","article-title":"Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors","volume":"3","author":"El-Sakka","year":"2006","journal-title":"J Sex Med"},{"key":"2024032522003553300_bb0105","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1111\/j.1743-6109.2009.01324.x","article-title":"Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function","volume":"6","author":"Jung","year":"2009","journal-title":"J Sex Med"},{"key":"2024032522003553300_bb0110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-410X.2009.08503.x","article-title":"Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"104","author":"Rosen","year":"2009","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0115","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-410X.2006.06171.x","article-title":"The beneficial effect of alfuzosin 10 mg once daily in \u201creal-life\u201d practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation","volume":"97","author":"Nickel","year":"2006","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1046\/j.1464-410X.2003.04229.x","article-title":"Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum","volume":"91","author":"Palea","year":"2003","journal-title":"BJU Int"},{"key":"2024032522003553300_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2003.08.009","article-title":"Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats","volume":"45","author":"Mayoux","year":"2004","journal-title":"Eur Urol"},{"key":"2024032522003553300_bb0130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1743-6109.2007.00754.x","article-title":"Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum","volume":"5","author":"Oger","year":"2008","journal-title":"J Sex Med"},{"key":"2024032522003553300_bb0135","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","article-title":"Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report","volume":"6","author":"Liguori","year":"2009","journal-title":"J Sex Med"},{"key":"2024032522003553300_bb0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-5347(05)00155-2","article-title":"Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily","volume":"175","author":"Hartung","year":"2006","journal-title":"J Urol"},{"key":"2024032522003553300_bb0145","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.ijir.3901554","article-title":"Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia","volume":"19","author":"Rosen","year":"2007","journal-title":"Int J Impot Res"},{"key":"2024032522003553300_bb0150","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1743-6109.2009.01663.x","article-title":"Impact of dry ejaculation caused by highly selective alpha1A-blocker: Randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men","volume":"7","author":"Shimizu","year":"2010","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515336638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515336638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/9\/2582\/47250018\/jsm_8_9_2582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/9\/2582\/47250018\/jsm_8_9_2582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T22:15:02Z","timestamp":1711404902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/8\/9\/2582\/6844740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,1]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02359.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,9,1]]}}}